Vext Science Inc
Vext Science, Inc., through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. The company al… Read more
Vext Science Inc (VEXTF) - Net Assets
Latest net assets as of September 2025: $68.41 Million USD
Based on the latest financial reports, Vext Science Inc (VEXTF) has net assets worth $68.41 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($128.09 Million) and total liabilities ($59.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $68.41 Million |
| % of Total Assets | 53.41% |
| Annual Growth Rate | 36.05% |
| 5-Year Change | 108.56% |
| 10-Year Change | N/A |
| Growth Volatility | 32.99 |
Vext Science Inc - Net Assets Trend (2017–2024)
This chart illustrates how Vext Science Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vext Science Inc (2017–2024)
The table below shows the annual net assets of Vext Science Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $75.74 Million | -20.26% |
| 2023-12-31 | $94.98 Million | +32.07% |
| 2022-12-31 | $71.92 Million | +21.09% |
| 2021-12-31 | $59.39 Million | +63.56% |
| 2020-12-31 | $36.31 Million | +41.44% |
| 2019-12-31 | $25.67 Million | +51.01% |
| 2018-12-31 | $17.00 Million | +93.75% |
| 2017-12-31 | $8.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vext Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 74.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $15.29 Million | 20.18% |
| Other Components | $60.45 Million | 79.82% |
| Total Equity | $75.74 Million | 100.00% |
Vext Science Inc Competitors by Market Cap
The table below lists competitors of Vext Science Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PPK Group Limited
PINK:PLPKF
|
$14.55 Million |
|
Alaska Energy Metals Corporation
OTCQB:AKEMF
|
$14.55 Million |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
$14.55 Million |
|
Chinese People Holdings Company Limited
F:KEH
|
$14.56 Million |
|
Eastwood Bio-Medical Canada Inc
PINK:EWOOF
|
$14.54 Million |
|
In The F
KO:014990
|
$14.54 Million |
|
Resilient Property Income Fund Ltd
JSE:RES
|
$14.54 Million |
|
FreeMs Corporation
KQ:053160
|
$14.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vext Science Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 94,982,275 to 75,735,677, a change of -19,246,598 (-20.3%).
- Net loss of 22,435,176 reduced equity.
- Other factors increased equity by 3,188,578.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.44 Million | -29.62% |
| Other Changes | $3.19 Million | +4.21% |
| Total Change | $- | -20.26% |
Book Value vs Market Value Analysis
This analysis compares Vext Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.31x to 0.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.47 | $0.15 | x |
| 2018-12-31 | $0.91 | $0.15 | x |
| 2019-12-31 | $1.14 | $0.15 | x |
| 2020-12-31 | $0.77 | $0.15 | x |
| 2021-12-31 | $0.84 | $0.15 | x |
| 2022-12-31 | $0.48 | $0.15 | x |
| 2023-12-31 | $0.44 | $0.15 | x |
| 2024-12-31 | $0.31 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vext Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -62.32%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.81x
- Recent ROE (-29.62%) is below the historical average (10.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 46.81% | 27.66% | 1.07x | 1.58x | $3.23 Million |
| 2018 | 22.05% | 20.29% | 0.79x | 1.38x | $2.05 Million |
| 2019 | 10.88% | 12.51% | 0.58x | 1.51x | $226.00K |
| 2020 | 5.85% | 8.43% | 0.45x | 1.53x | $-1.51 Million |
| 2021 | 8.40% | 13.39% | 0.44x | 1.41x | $-952.64K |
| 2022 | 15.18% | 30.84% | 0.29x | 1.68x | $3.73 Million |
| 2023 | 4.63% | 12.63% | 0.23x | 1.57x | $-5.10 Million |
| 2024 | -29.62% | -62.32% | 0.26x | 1.81x | $-30.01 Million |
Industry Comparison
This section compares Vext Science Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vext Science Inc (VEXTF) | $68.41 Million | 46.81% | 0.87x | $14.55 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |